The development of toxoid vaccines involves several steps. First, the bacterial toxin is isolated and purified. This toxin is then inactivated, usually by treating it with a chemical such as formaldehyde, rendering it non-toxic but still immunogenic. The inactivated toxin, or toxoid, is then formulated with adjuvants to enhance the immune response. The final product is tested for safety and efficacy before it is approved for use.
